OVARIAN CANCER and US: epithelial ovarian cancer

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label epithelial ovarian cancer. Show all posts
Showing posts with label epithelial ovarian cancer. Show all posts

Saturday, January 21, 2012

abstract: Natural history and outcome of mucinous carcinoma of the ovary (women dx'd 1988 to 2007)



Blogger's Note: this conclusion therefore begs an obvious question

OBJECTIVE:

We performed a population-based analysis to compare the clinical characteristics of women with mucinous tumors with women with other epithelial tumors. (SEER stats)

 CONCLUSION:

Although survival for early-stage mucinous and serous tumors is similar, survival for advanced-stage mucinous neoplasms is inferior to that of serous carcinomas.

Sunday, August 08, 2010

abstract: How to follow-up patients with epithelial ovarian cancer : Current Opinion in Oncology



How to follow-up patients with epithelial ovarian cancer
Miller, Rowan E; Rustin, Gordon JS

Abstract

Purpose of review:
Despite optimal primary treatment most patients with advanced epithelial ovarian cancer will relapse. This review discusses the controversy regarding surveillance and the timing of treatment for recurrent disease.

Recent findings
: Routine physical examination has a limited role in the detection of recurrent ovarian cancer. PET/computed tomography (CT) has been shown to be useful in detecting small volume disease not apparent on traditional imaging in patients with suspected recurrence based on symptoms and/or rising CA125. The results of PET/CT can alter treatment plans and have particular use in guiding site-directed therapy. The benefits of early detection and systemic treatment of recurrence are now in doubt following the presentation of the MRC/EORTC CA125 surveillance trial. The impact on survival of secondary cytoreductive surgery requires more investigation.

Summary:
Uncertainties remain in the surveillance and timing of treatment for relapsed disease. Patients should be informed of these uncertainties and become involved in decisions regarding their follow-up.